SAHPRA MedSafetyWeek campaign: Reporting of Side Effects

By HEOR Staff Writer

November 11, 2023

SAHPRA MedSafetyWeek campaign

The Importance of Documenting Side Effects

The South African Health Products Regulatory Authority (SAHPRA) is advocating for the usage of the MedSafety app as a means of bolstering efforts to ensure the integrity of medicinal products. #MedSafetyWeek is a global campaign that aims to improve the safety of medications all around the world, and this project is a component of that campaign. The campaign, involving more than 80 regulatory agencies, is a testament to the collective effort to better the healthcare industry.

 

SAHPRA MedSafetyWeek campaign: A Tool for Safer Medicines

Patients, physicians, nurses, and pharmacists are all able to report adverse effects with the help of a powerful tool called the MedSafety app. These reports are absolutely necessary for the continuous monitoring of the medications’ safety. According to Mafora Matlala, the Pharmacovigilance Manager at SAHPRA, “Every report is important in building more knowledge and understanding of the benefits and risks of medicines in clinical use and allows action to be taken to minimise risks.”

Users can download the MedSafety app from the Google Play Store or the Apple App Store, depending on your device. The app allows users to report adverse events and product quality issues. This helps enhance the safety of the healthcare environment overall.

SAHPRA’s commitment to the safety, efficacy, and quality of all health products underlines its ethos. Together, we can make a difference in ensuring safer medicines for all.

Reference url

Recent Posts

Levacetylleucine A-T treatment
Transformative Impact of Levacetylleucine A-T Treatment in Rare Neurodegenerative Disease

By HEOR Staff Writer

June 8, 2026

Levacetylleucine A-T treatment has delivered compelling Phase III results, producing statistically significant and clinically meaningful improvements in ataxia severity and daily function for both pediatric and adult patients with ataxia-telangiectasia (A-T). The
Insulin Cost Policy Impact
Insulin Cost Policy Impact on Medicare Beneficiaries

By HEOR Staff Writer

June 8, 2026

The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...
mifepristone safety study
Mifepristone Safety Study: Ensuring Continued Regulatory Oversight

By João L. Carapinha

June 6, 2026

The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms. S...